New chemo combo shows promise for tough pancreatic tumors
NCT ID NCT07043270
First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 2 times
Summary
This study tests a new way of giving chemotherapy to people with pancreatic cancer that is on the edge of being removable. The goal is to shrink the tumor enough for successful surgery. About 35 adults will receive two different chemo drug combinations in alternating cycles. The main focus is on how long people stay free of cancer progression or death after one year.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BORDERLINE RESECTABLE PANCREATIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Dartmouth-Hitchcock Medical Center
RECRUITINGLebanon, New Hampshire, 03756, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Four-Drug cocktail aims to shrink pancreatic tumors before surgery
- Could a simple blood test catch pancreatic cancer before It's too late?
- Scientists hunt for clues to prevent a common complication after pancreatic cancer surgery
- New drug THE-0504 enters human testing for tough cancers
- Could a common blood pressure pill boost radiation against tough pancreatic tumors?
- Blood test could guide pancreatic cancer therapy